Comparison of targeted and whole genome analysis of postnatal specimens using a commercially available array based comparative genomic hybridisation (aCGH) microarray platform. Issue 5 (4th January 2008)

• Record Type: Journal Article
• Authors: Aston, E; Whitby, H; Maxwell, T; Glaus, N; Cowley, B; Lowry, D; Zhu, X L; Issa, B; South, S T; Brothman, A R
• Is Part Of: Journal of medical genetics. Volume 45:Issue 5(2008)
• Page Start: 268
• Page End: 274
• Publication Date: 2008-01-04
• Subjects: Medical genetics -- Periodicals; 616.042
• DOI: 10.1136/jmg.2007.055319
• Languages: English
• ISSNs: 1468-6244

Abstract

Abstract : Purpose: The University of Utah Comparative Genomic Hybridization Microarray Laboratory was one of the first US laboratories to offer comparative genomic hybridisation (CGH) microarray testing using a commercial platform in a clinical setting. Results for 1076 patients (1598 chips) are presented. Methods: The Spectral Genomics/PerkinElmer Constitutional Chip TM (targeted array), SpectralChip 2600 TM (whole genome array) and a "Combo" chip (both arrays run simultaneously) were the tests offered. Abnormal results were confirmed by an alternative method, most often fluorescence in situ hybridisation. Results: In 669 cases with known normal cytogenetics, an abnormal detection rate of 10.8% was observed, (5.3%, 12.2% and 14.1% for the Constitutional Chip TM, SpectralChip 2600 TM and Combo assay, respectively). Known copy number variants and single clone abnormalities are not included in these rates. Single clone abnormalities are reported separately. For 1076 total cases, we report an average abnormal rate of 16.9% (8.7%, 23.7% and 18.6% for the three assays). This rate includes characterisation of some abnormalities previously identified by cytogenetics. Conclusions: CGH microarray provides a likely aetiology for the clinical phenotype in many cytogenetically normal cases, and a whole genome array generally identifies copy number changes more effectively than a targeted chip alone.